Form 8-K Cara Therapeutics, Inc. For: May 23
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil hovers near $100 on rising Middle East tensions
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Cara Therapeutics (CARA) PT Raised to $24 at H.C. Wainwright; 'Premier Partnership Incrementally De-Risks IV Korsuva'
May 23, 2018 12:44 PM EDTH.C. Wainwright raised its price target on Cara Therapeutics (NASDAQ: CARA) to $24.00 (from $22.00) while maintaining a Neutral rating.
... MoreCara Therapeutics (CARA) PT Raised to $20 at Stifel Following Vifor-Fresenius JV
May 23, 2018 11:01 AM EDTStifel raised its price target on Cara Therapeutics (NASDAQ: CARA) to $20.00 (from $17.00) while maintaining a Buy rating after the company announced a licensing arrangement with Vifor Fresenius Medical Care Renal Pharma (VFMCRP)a joint venture between Vifor Pharma (market leading provider of renal drugs) and... More
